CFA
NKTR icon

Camarda Financial Advisors’s Nektar Therapeutics NKTR Stock Holding History

Camarda Financial Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-13
Closed -$3K – 240
2016
Q2 		$3K Buy
+13
New +$2.91K ﹤0.01% 237

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Camarda Financial Advisors's NKTR Position: Q3 2016 in Review

Camarda Financial Advisors sold out of Nektar Therapeutics (NKTR) in Q3 2016, closing a stake of 13 shares — an estimated $3K sold.

Camarda Financial Advisors first reported a position in NKTR in Q2 2016 and held it in 1 quarter. The position peaked at $3K in Q2 2016. 194 funds tracked by Wall St. Rank hold NKTR as of Q3 2016.

  • Camarda Financial Advisors reported no remaining Nektar Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Camarda Financial Advisors sold 13 Nektar Therapeutics shares in Q3 2016, an estimated $3K.
  • Camarda Financial Advisors first reported a position in Nektar Therapeutics in Q2 2016 and held it in 1 quarter.
  • Camarda Financial Advisors's Nektar Therapeutics position peaked at $3K in Q2 2016.
  • 194 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2016.

Based on Camarda Financial Advisors's 13F filing for Q3 2016, filed 10 Nov 2016.